Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies - Full Text View

Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

This study has been terminated.

Sponsored by:	M.D. Anderson Cancer Center
Information provided by:	M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT00038883

Purpose

High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive properties.

Condition	Intervention
Leukemia, Lymphocytic, Chronic Leukemia, Lymphocytic, Acute Lymphoma, Low-Grade Lymphoma, T-Cell Lymphoma, B-Cell	Drug: Campath-1H

MedlinePlus related topics:

Cancer Leukemia, Adult Acute Leukemia, Adult Chronic Leukemia, Childhood Lymphoma

Drug Information available for:

Alemtuzumab Campath

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Official Title:	Campath-1H Snd Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

Further study details as provided by M.D. Anderson Cancer Center:

Estimated Enrollment:	142
Study Start Date:	April 2001

Eligibility

Ages Eligible for Study:	15 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Patients with CLL, ALL, low grade Lymphoma, B and T cell Lymphoma of the intermediate and high grade (if not eligible for autologous transplant) CD52 expression of >20% by flow cytometry.
Patients in relapse after conventional treatment.
Patients with an HLA-identical or one-antigen mismatched sibling, or matched unrelated donor.
Patients previously exposed to Campath-1H treatment response. Patient must be at least 2 months or later from the last dose of Campath-1H.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00038883

Locations


United States, Texas
	MDAnderson Cancer Center
	Houston, Texas, United States, 77030

Sponsors and Collaborators

M.D. Anderson Cancer Center

More Information

Study ID Numbers:	ID99-410
First Received:	June 5, 2002
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00038883
Health Authority:	United States: Food and Drug Administration

Keywords provided by M.D. Anderson Cancer Center:

Lymphoid Malignancies

Chronic Lymphocytic Leukemia

Acute Lymphoblastic Leukemia

Low grade Lymphoma

B and T cell Lymphoma of the intermediate and high grade

Study placed in the following topic categories:

Chronic lymphocytic leukemia

Leukemia, Lymphoid

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Immunoproliferative Disorders

Lymphoma, B-Cell

Leukemia

Lymphatic Diseases

Leukemia, Lymphocytic, Chronic, B-Cell

Alemtuzumab

Lymphoma, T-Cell

B-cell lymphomas

Leukemia, B-Cell

Lymphoma, Non-Hodgkin

Lymphoproliferative Disorders

Lymphoma

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Histologic Type

Immune System Diseases

Antineoplastic Agents

Therapeutic Uses

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008